Prosecution Insights
Last updated: April 19, 2026

K&L Gates - Novartis

14 pending office actions • 4 clients

Portfolio Summary

14
Total Pending OAs
5
Final Rejections
9
Non-Final OAs

Client Portfolio (4 clients)

Client (Assignee)Pending OAs
Novartis AG 7
The Trustees of the University of Pennsylvania 5
The Medical College of Wisconsin, Inc. 1
Novartis AG 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18629314 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION Novartis AG HUYNH, PHUONG N 1641 Non-Final OA Apr 08, 2024
18288345 VIRAL VECTOR PRODUCTION SYSTEM Novartis AG STAVROU, CONSTANTINA E 1632 Non-Final OA Oct 25, 2023
18454457 ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF Novartis AG BENAVIDES, JENNIFER ANN 1675 Non-Final OA Aug 23, 2023
18351151 BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME The Trustees of the University of Pennsylvania HALVORSON, MARK 1646 Final Rejection Jul 12, 2023
18326373 METHODS FOR TREATING HEMATOLOGIC CANCERS The Medical College of Wisconsin, Inc. OUSPENSKI, ILIA I 1644 Non-Final OA May 31, 2023
18309370 CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORE The Trustees of the University of Pennsylvania GRABER, JAMES J 1631 Final Rejection Apr 28, 2023
18184860 BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF Novartis AG SKELDING, ZACHARY S 1644 Non-Final OA Mar 16, 2023
18178886 SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES Novartis AG HUYNH, PHUONG N 1641 Final Rejection Mar 06, 2023
17433812 MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY Novartis AG EBBINGHAUS, BRIANA NOEL 1632 Non-Final OA Aug 25, 2021
17161929 CHO CELL EXPRESSED HET IL-15 Novartis AG CARTER, SANDRA DILLAHUNT 1674 Non-Final OA Jan 29, 2021
16608515 BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR Novartis AG LU, CHENG 1642 Non-Final OA Oct 25, 2019
16435257 TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR The Trustees of the University of Pennsylvania BRISTOL, LYNN ANNE 1643 Final Rejection Jun 07, 2019
16317943 TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR The Trustees of the University of Pennsylvania LU, CHENG 1642 Final Rejection Jan 15, 2019
16093758 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION The Trustees of the University of Pennsylvania MARTINEZ, TARA L 1654 Non-Final OA Oct 15, 2018

Managing K&L Gates - Novartis's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month